Dianthus Therapeutics (DNTH) Invested Capital (2017 - 2025)
Historic Invested Capital for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $546.5 million.
- Dianthus Therapeutics' Invested Capital rose 6172.16% to $546.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.5 million, marking a year-over-year increase of 6172.16%. This contributed to the annual value of $352.5 million for FY2024, which is 10872.68% up from last year.
- Latest data reveals that Dianthus Therapeutics reported Invested Capital of $546.5 million as of Q3 2025, which was up 6172.16% from $303.1 million recorded in Q2 2025.
- Over the past 5 years, Dianthus Therapeutics' Invested Capital peaked at $546.5 million during Q3 2025, and registered a low of -$61.5 million during Q2 2023.
- In the last 4 years, Dianthus Therapeutics' Invested Capital had a median value of $178.4 million in 2023 and averaged $202.8 million.
- Its Invested Capital has fluctuated over the past 5 years, first tumbled by 14529.84% in 2023, then skyrocketed by 83334.71% in 2024.
- Over the past 4 years, Dianthus Therapeutics' Invested Capital (Quarter) stood at -$44.4 million in 2022, then surged by 480.61% to $168.9 million in 2023, then surged by 108.73% to $352.5 million in 2024, then soared by 55.03% to $546.5 million in 2025.
- Its Invested Capital was $546.5 million in Q3 2025, compared to $303.1 million in Q2 2025 and $328.6 million in Q1 2025.